






Expression Engineering Experiment	
Lecture 1	Lecture 2
 intro to cell culture 	 transfection
 intro to gene exp'n/RNAi 	 luciferase
Lecture 3	Lecture 4
off-target/nonspecific RNAi	 Writing lecture
	(Neal Lerner)
Lecture 5	Lecture 6
 measuring gene express'n 	 microarray analysis (Rebecca Fry)
Lecture 7	Lecture 8
 high throughput technologies or RNAi applications (no lab) 	 review of your data























Treatment Evaluation Tool: will tumor be hormone-responsive?



 ${\sim}75\%$ of all breast cancers are ER+ (estrogen receptor positive), with remaining 25% negative or an unknown status

 \sim About 65% of all ER+ are also PR+ (progesterone receptor positive)


~ 10% of breast cancers are ER+ and PR-

~ 5% of breast cancers are ER- and PR+

Cancergeek.com

Treatment Evaluation Tool: how likely is it to spread?

Most commonly spreads to lymph tissue



"Chemotherapy and/or hormonal therapy reduce the risk of distant metastases by approximately one-third; however, 70-80% of patients receiving this treatment would have survived without it." Agendia

